Condition: Weight Management · Sponsor: AstraZeneca
This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Birmingham, Alabama, United States | Not Yet Recruiting |
| Research Site | Dothan, Alabama, United States | Not Yet Recruiting |
| Research Site | Chandler, Arizona, United States | Not Yet Recruiting |
| Research Site | Peoria, Arizona, United States | Not Yet Recruiting |
| Research Site | Little Rock, Arkansas, United States | Not Yet Recruiting |
| Research Site | Lynwood, California, United States | Not Yet Recruiting |
| Research Site | Rolling Hills Estates, California, United States | Not Yet Recruiting |
| Research Site | Sacramento, California, United States | Not Yet Recruiting |
| Research Site | Arvada, Colorado, United States | Not Yet Recruiting |
| Research Site | New Haven, Connecticut, United States | Not Yet Recruiting |
| Research Site | Clearwater, Florida, United States | Not Yet Recruiting |
| Research Site | Plantation, Florida, United States | Not Yet Recruiting |
+ 309 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07667803